DAFNA Capital Management LLC Raises Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

DAFNA Capital Management LLC boosted its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 12.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 811,678 shares of the specialty pharmaceutical company's stock after acquiring an additional 88,000 shares during the quarter. KalVista Pharmaceuticals accounts for about 1.7% of DAFNA Capital Management LLC's portfolio, making the stock its 18th largest position. DAFNA Capital Management LLC owned 1.64% of KalVista Pharmaceuticals worth $6,875,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Aquatic Capital Management LLC acquired a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at about $44,000. Tower Research Capital LLC TRC lifted its holdings in KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after buying an additional 5,502 shares during the period. Legal & General Group Plc grew its holdings in KalVista Pharmaceuticals by 22.5% during the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock worth $69,000 after acquiring an additional 1,494 shares during the period. Martin Worley Group bought a new position in shares of KalVista Pharmaceuticals in the 4th quarter worth about $86,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of KalVista Pharmaceuticals by 24.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock valued at $87,000 after purchasing an additional 2,043 shares during the period.

Analysts Set New Price Targets

KALV has been the subject of a number of research analyst reports. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Jones Trading restated a "buy" rating and issued a $30.00 price target on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an "outperform" rating and a $19.00 price objective on the stock. Citizens Jmp raised KalVista Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 31st. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, KalVista Pharmaceuticals has an average rating of "Buy" and a consensus price target of $24.83.

KalVista Pharmaceuticals Trading Down 3.9%

NASDAQ KALV traded down $0.47 during trading hours on Tuesday, hitting $11.71. The company's stock had a trading volume of 241,693 shares, compared to its average volume of 417,383. The company has a market capitalization of $582.17 million, a PE ratio of -3.22 and a beta of 0.05. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $15.50. The company's 50-day simple moving average is $12.05 and its two-hundred day simple moving average is $10.41.

Insider Buying and Selling

In related news, CEO Benjamin L. Palleiko sold 5,104 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $50,121.28. Following the completion of the sale, the chief executive officer now owns 278,855 shares in the company, valued at approximately $2,738,356.10. This trade represents a 1.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Venrock Healthcare Capital Par bought 100,000 shares of the stock in a transaction on Wednesday, February 12th. The stock was purchased at an average price of $9.23 per share, for a total transaction of $923,000.00. Following the completion of the purchase, the insider now owns 5,217,285 shares of the company's stock, valued at approximately $48,155,540.55. This trade represents a 1.95% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 17,292 shares of company stock worth $184,625. 10.50% of the stock is owned by corporate insiders.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).